Reduced saliva, slowed digestion, acid reflux, and ketone release from fat burning can all play a role
Semaglutide works by slowing gastric emptying and suppressing appetite, which leads to reduced food intake and weight loss
Akhavan A, Bershad S
Review these policies before making purchases to understand your options if issues arise
Novo Nordisk already has an oral version of semaglutide, the active ingredient in Ozempic and Wegovy, on the market in Rybelsus, which was first approved in 2019, but that is indicated for treating Type 2 diabetes, not obesity
For regulatory status of GLP-1 compounds including which are FDA-approved vs research-only, see our complete FDA approved peptides list